Literature DB >> 81361

Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.

M Maebashi, N Kawamura, M Sato, A Imamura, K Yoshinaga.   

Abstract

Serum-lipid concentrations were determined in patients with type-IV hyperlipoproteinaemia treated with 900 mg/day oral DL-carnitine chloride. Serum-triglyceride was significantly reduced and concentrations continued to decline as carnitine administration continued. Total and esterified cholesterol concentrations did not change. Intravenous infusion of carnitine produced the same effects. The results suggest that carnitine is of value in the therapy of type-IV hyperliproteinaemia. Increased oxidation of free fatty acids in the tissues seems to account for the effects of carnitine on serum-lipid concentrations.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 81361     DOI： 10.1016/s0140-6736(78)92587-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  10 in total

1.  Genomic interval engineering of mice identifies a novel modulator of triglyceride production.

Authors:  Y Zhu; M C Jong; K A Frazer; E Gong; R M Krauss; J F Cheng; D Boffelli; E M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Serum levels of carnitine, apolipoprotein A I, and apolipoprotein B in children with nephrotic proteinuria.

Authors:  Z Bircan; A Kaplan; M Söker; S Batun; A Sahin; M Soran
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

3.  L-Carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets.

Authors:  M Diaz; F Lopez; F Hernandez; J A Urbina
Journal:  Lipids       Date:  2000-06       Impact factor: 1.880

4.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

5.  L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Authors:  M Florentin; M S Elisaf; C V Rizos; V Nikolaou; E Bilianou; C Pitsavos; E N Liberopoulos
Journal:  Lipids       Date:  2016-12-02       Impact factor: 1.880

6.  Relationship between acid-soluble carnitine and coenzyme A pools in vivo.

Authors:  E P Brass; C L Hoppel
Journal:  Biochem J       Date:  1980-09-15       Impact factor: 3.857

7.  [Decreased plasma carnitine in Type I diabetes mellitus].

Authors:  P Pregant; G Schernthaner; E Legenstein; L Lienhart; S Bruck; C Schnack; E Kaiser
Journal:  Klin Wochenschr       Date:  1991-08-16

Review 8.  Carnitine in human nutrition.

Authors:  A C Bach
Journal:  Z Ernahrungswiss       Date:  1982-12

9.  L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.

Authors:  Marcello Romano; Marco Vacante; Erika Cristaldi; Valentina Colonna; Maria Pia Gargante; Lisa Cammalleri; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

Review 10.  The effects of L-carnitine supplementation on lipid concentrations inpatients with type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.

Authors:  Omid Asbaghi; Sara Kashkooli; Mohammad Reza Amini; Hossein Shahinfar; Kurosh Djafarian; Cain C T Clark; Sakineh Shab-Bidar
Journal:  J Cardiovasc Thorac Res       Date:  2020-09-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.